Table 4.
Clinicopathological characteristics of all patients with different treatments.
| Characteristics | Monotherapy (N=17) (%) | With chemotherapy (N=15) (%) | With anlotinib (N=14) (%) | p value |
|---|---|---|---|---|
| Age | ||||
| Median, range | 61(39-80) | 66(54-78) | 59 (41-78) | 0.081 |
| Sex | 0.763 | |||
| Male | 19 (59.4) | 13 (50.0) | 16 (57.1) | |
| Female | 13 (40.6) | 13 (50.0) | 12 (42.9) | |
| Smoking history | 0.471 | |||
| Yes | 18 (56.2) | 11 (42.3) | 12 (42.9) | |
| No | 14 (43.8) | 15 (57.7) | 16 (57.1) | |
| Recurrence after surgery | 0.800 | |||
| Yes | 16 (50.0) | 11 (42.3) | 12 (42.9) | |
| No | 16 (50.0) | 15 (57.7) | 16 (57.1) | |
| Treatment line of PD-1 Inhibitors | 0.862 | |||
| Second line | 2 (6.3) | 1 (3.8) | 1 (3.6) | |
| Third/after line | 30 (93.7) | 25 (96.2) | 27 (96.4) | |
| Brain metastasis | 0.700 | |||
| Yes | 6 (18.8) | 5 (19.2) | 6 (21.4) | |
| No | 26 (81.2) | 21 (80.8) | 22 (78.6) | |
| PD-L1 TPS | 0.131 | |||
| <1% | 8 (25.0) | 1 (3.8) | 8 (28.6) | |
| 1~49% | 13 (40.6) | 13 (50.0) | 6 (21.4) | |
| ≥50% | 9 (28.1) | 8 (30.8) | 9 (32.1) | |
| Unknown | 2 (6.3) | 4 (15.4) | 5 (17.9) | |
| EGFR mutation subtype | 0.152 | |||
| 19del | 5 (1.6) | 6 (23.1) | 11 (39.3) | |
| 21L858R | 21 (65.6) | 17 (65.4) | 9 (32.1) | |
| T790M | 3 (9.4) | 1 (3.8) | 4 (14.3) | |
| Others | 3 (9.4) | 2 (7.7) | 4 (14.3) |